Innate Pharma SA Profit Loss From Continuing Operations
Innate Pharma SA (IPHYF) reported Profit Loss From Continuing Operations of -EUR 49.18 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Notes
ifrs-full:ProfitLossFromContinuingOperations · last filed 2026-04-01
| Period end | Profit Loss From Continuing Operations 6 month | Profit Loss From Continuing Operations 12 month |
|---|---|---|
| 2025-12-31 | -49.18M EUR 20-F · filed 2026-04-01 | |
| 2024-12-31 | -49.47M EUR 20-F · filed 2026-04-01 | |
| 2023-12-31 | -7.57M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 1.72M EUR 6-K · filed 2023-09-14 | |
| 2022-12-31 | -57.97M EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 6.38M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | -45.48M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | -17.47M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | -829.00K EUR 20-F · filed 2023-04-06 | |
| 2019-12-31 | 7.87M EUR 20-F · filed 2022-04-04 |